Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01717053 · ClinicalTrials.gov registry record · Phase 2
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT01717053 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 37 participants.
The verdict
NCT01717053, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The addition of abiraterone acetate to standard treatment of radiotherapy and short-term androgen deprivation will increase the frequency of undetectable PSA.
Interventions
- RADIATION Radiation Therapy
- DRUG Prednisone
- DRUG Abiraterone acetate
- DRUG Androgen deprivation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2014-01-17 |
| Est. Completion | 2021-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01717053
The ClinicalTrials.gov registry entry for NCT01717053 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Radiation Therapy is the first listed.
NCT01717053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01717053 about?
NCT01717053 is a clinical study titled "Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer". The addition of abiraterone acetate to standard treatment of radiotherapy and short-term androgen deprivation will increase the frequency of undetectable PSA.
What is the current status of trial NCT01717053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2014-01-17. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT01717053?
The interventions under investigation include: Radiation Therapy (RADIATION), Prednisone (DRUG), Abiraterone acetate (DRUG), Androgen deprivation (DRUG).
Who is sponsoring clinical trial NCT01717053?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.